Effect of pomegranate tea on symptom relief of COVID-19 patients

INTERVENTION: Intervention 1: Intervention group: Participants in the intervention group receive 4 times a day (after each meal and before bedtime) and 10 ccs of pomegranate syrup for 21 days each time, in addition to standard treatment. Pomegranate tea is prepared by dilution 10 ccs of pomegranate syrup in 50 to 100 cc of warm boiled water and kept in the mouth for a while before swallowing. Intervention 2: Control group: In addition to standard treatment, the control group receives a placebo in completely similar conditions. The placebo will be produced in terms of taste and color similar to the original drug and will be used in completely similar conditions. CONDITION: COVID‐19. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Duration of Hospitalization. Timepoint: Every day after randomization. Method of measurement: Patients' medical records. Time to clinical deterioration. Timepoint: Every day after randomization. Method of measurement: Patients' medical records. Time to clinical improvement. Timepoint: Every day after randomization. Method of measurement: Patients' medical records. INCLUSION CRITERIA: Positive diagnostic specimen on RT‐PCR Men or non‐pregnant women over 18 years of age Significant involvement in pulmonary CT scan with pneumonia diagnosis Oxygen saturation (Sao2) of blood less than or equal to 93% in room air Respiratory rate above 24 per minute SECONDARY OUTCOME: Blood cell count. Timepoint: Two days in between after randomization. Method of measurement: The complete blood count (CBC). Chills. Timepoint: Every day after randomization. Method of measurement: Clinical observation and history taking. Clinical improvement in first 7 days of intervention. Timepoint: 7th day after randomization. Method of measurement: Patients' medical records. Cough. Timepoint: Every day after randomization. Method of measurement: Clinical observation and history taking. CRP level. Timepoint: Two days in between after randomization. Method of measurement: Blood test. Duration of respiratory support. Timepoint: Every day after randomization. Method of measurement: Patients' medical records. Dyspnea. Timepoint: Every day after randomization. Method of measurement: Clinical observation and history taking. Fatigue. Timepoint: Every day after randomization. Method of measurement: Clinical observation and history taking. Ferritin. Timepoint: Two days in between after randomization. Method of measurement: Blood test. Fever. Timepoint: Every day after randomization. Method of measurement: Thermometer. Gastrointestinal adverse events. Timepoint: Every day after randomization. Method of measurement: Clinical observation and history taking. Headache. Timepoint: Every day after randomization. Method of measurement: Clinical observation and history taking. Lactate dehydrogenase. Timepoint: Two days in between after randomization. Method of measurement: Blood test. Mortality. Timepoint: 21th day after randomization. Method of measurement: Patients' medical records. Myalgia. Timepoint: Every day after randomization. Method of measurement: Clinical observation and history taking. Oxygen saturation. Timepoint: Every day after randomization. Method of measurement: Pulse Oximeter. Respiratory rate. Timepoint: Every day after randomization. Method of measurement: Clinical observation and examination. SARS‐CoV‐2 test result. Timepoint: 21th day after randomization. Method of measurement: RT‐PCR. Serum creatinine. Timepoint: Two days in between after randomization. Method of measurement: Blood test. Sore throat. Timepoint: Every day after randomization. Method of measurement: Clinical observation and history taking. Systolic blood pressure. Timepoint: Every day after randomization. Method of measurement: Clinical observation and examination. Thirsty. Timepoint: Every day after randomization. Method of measurement: Clinical observation and history taking. Transmission to ICU. Timepoint: Every day after randomization. Method of measurement: Patients' medical records.